DT
Daniel Gedeon Teper
CEODirector10% Owner

Daniel Gedeon Teper insider trades: Immune Pharmaceuticals (IMNP) stock purchases

CEO, Immune Pharmaceuticals Last trade Aug 4, 2016 19 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2015
2
Companies
last trade 2016

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Daniel reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 4, 2016IMNP↑ Buy$356K
Jan 26, 2016IMNP↑ Buy10b5-1$25K
Jan 19, 2016IMNP↑ Buy10b5-1$25K
Jan 12, 2016IMNP↑ Buy10b5-1$25K
Jan 5, 2016IMNP↑ Buy10b5-1$50K
Dec 7, 2015IMNP↑ Buy$50K
Oct 26, 2015IMNP↑ Buy10b5-1$25K
Oct 19, 2015IMNP↑ Buy10b5-1$25K
Oct 12, 2015IMNP↑ Buy10b5-1$25K
Oct 5, 2015IMNP↑ Buy10b5-1$50K
Sep 1, 2015IMNP↑ Buy$10K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Daniel Gedeon Teper's insider trades

Daniel Gedeon Teper is CEO at Immune Pharmaceuticals (IMNP). Since Sep 1, 2015, Daniel has reported 11 open-market purchases worth $665K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (5 filings), other transactions (2 filings), option exercises (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMNP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.